Site icon Market Globalist

Ocugen Inc. (NASDAQ: OCGN) stock falls during pre-market. Here’s to know why?

Ocugen Inc. (NASDAQ: OCGN) stock plunged by 4.12% at last close while the OCGN stock price continues to decline by 4.52% in the pre-market trading. Ocugen is a biopharmaceutical company specializing in the discovery, development, and commercialization of gene therapy to treat blindness and the development of a COVID-19 vaccine. Our ground-breaking modifier gene therapy platform holds the promise of treating many retinal disorders with a single drug.

Financial Results

On May 7, 2021, OCGN announced its first-quarter 2021 financial highlights. Given below is the summary:

Read More

Dr. Shankar Musunuri CEO and Co-Founder of Ocugen commented:

Ocugen’s commitment to saving lives from COVID-19 continues with the launch of COVAXIN in the United States, as well as the advancement of their ophthalmology gene therapy pipeline. OCGN presented the second interim review findings from Bharat Biotech’s Phase 3 clinical trial in India, as well as promising in-vitro evidence on COVAXIN’s potential to neutralize new variants. OCGN is continuing to work on an Emergency Use Authorization for COVAXIN, while also considering therapeutic development in special populations, such as infants, and booster doses. OCGN is also pleased to have raised new capital to support current and prospective activities.

Exit mobile version